Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 20/20 | 0.75 |
| ▸ | MMP3 | P08254 | 10/20 | 0.75 |
| ▸ | MMP1 | P03956 | 1/20 | 0.66 |
| ▸ | MMP9 | P14780 | 1/20 | 0.66 |
| ▸ | MMP14 | P50281 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7761449 | 0.95 | MMP2 (0.83) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL7763178 | 0.91 | MMP2 (0.74) | MMP2MMP3 | |
| SCHEMBL7762285 | 0.86 | MMP2 (0.82) | MMP2MMP3 | |
| SCHEMBL7763773 | 0.86 | MMP3 (0.62) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL7758488 | 0.79 | MMP2 (0.56) | MMP2MMP3MMP1MMP9MMP14 | |
| Methyl Benzoate SCHEMBL7763173 | 0.78 | MMP2 (0.48) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL7762295 | 0.76 | MMP2 (0.62) | MMP2MMP3 | |
| SCHEMBL8664107 | 0.75 | MMP2 (0.80) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL7758581 | 0.74 | MMP3 (0.61) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL7051257 | 0.74 | MMP2 (0.49) | MMP2MMP3MMP1MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |